Jacob Sands, MD
Medical oncologist and lung cancer expert at Dana-Farber Cancer Institute, providing clinical expertise on antibody–drug conjugates (ADCs) and practical toxicity management strategies.
Best podcasts with Jacob Sands, MD
Ranked by the Snipd community
Dec 13, 2025 • 25min
Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands
Dr. Jacob Sands, a leading medical oncologist at Dana-Farber Cancer Institute, shares his expertise on antibody-drug conjugates (ADCs) and their impact on non-small cell lung cancer (NSCLC). He highlights the side effects of various ADCs like Trastuzumab deruxtecan, detailing risks such as interstitial lung disease and mucositis. Proactive strategies for managing toxicities are discussed, with insights on patient education and monitoring. This conversation is a goldmine for healthcare professionals seeking to enhance patient care and navigate the challenges of these innovative therapies.
Sep 12, 2025 • 23min
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
In this engaging conversation, Dr. Jacob Sands, a medical oncologist at Dana-Farber Cancer Institute, dives deep into the exciting world of TROP2-directed antibody-drug conjugates for non-small cell lung cancer. He discusses how to manage adverse events like stomatitis and interstitial lung disease associated with datopotamab deruxtecan. Dr. Sands also highlights the drug's impressive intracranial efficacy and explores the promising role of combining ADCs with immunotherapy, revealing potential breakthroughs in treatment strategies.
